4.60
Schlusskurs vom Vortag:
$4.41
Offen:
$4.38
24-Stunden-Volumen:
279.46K
Relative Volume:
0.10
Marktkapitalisierung:
$112.91M
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
+7.23%
1M Leistung:
+36.90%
6M Leistung:
+191.14%
1J Leistung:
-56.52%
Artiva Biotherapeutics Inc Stock (ARTV) Company Profile
Firmenname
Artiva Biotherapeutics Inc
Sektor
Branche
Telefon
(858) 267-4467
Adresse
5505 MOREHOUSE DRIVE, SAN DIEGO
Vergleichen Sie ARTV mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
|
ARTV
Artiva Biotherapeutics Inc
|
4.60 | 108.24M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.15 | 118.84B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
812.27 | 81.61B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
422.50 | 53.69B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
822.94 | 49.49B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
176.00 | 37.34B | 447.02M | -1.18B | -906.14M | -6.1812 |
Artiva Biotherapeutics Inc Stock (ARTV) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-06-11 | Fortgesetzt | H.C. Wainwright | Buy |
| 2024-12-30 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-08-13 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-08-13 | Eingeleitet | Jefferies | Buy |
| 2024-08-13 | Eingeleitet | Needham | Buy |
| 2024-08-13 | Eingeleitet | TD Cowen | Buy |
| 2024-08-13 | Eingeleitet | Wedbush | Outperform |
Alle ansehen
Artiva Biotherapeutics Inc Aktie (ARTV) Neueste Nachrichten
Artiva Biotherapeutics (NASDAQ:ARTV) Trading Up 4.3% – Should You Buy? - Defense World
Genelux Corporation Announces Appointment of Jason Litten as Chief Medical Officer, Effective January 2, 2026 - marketscreener.com
Will Artiva Biotherapeutics Inc. stock gain from lower inflationJuly 2025 Levels & Risk Controlled Swing Alerts - Улправда
Artiva Biotherapeutics (ARTV): Evaluating Valuation After CEO’s Latest Insider Share Sale - Yahoo Finance
Will Artiva Biotherapeutics Inc. stock deliver long term returnsMarket Risk Summary & Reliable Entry Point Alerts - Улправда
Artiva Biotherapeutics Reports Increased Losses Amid Ongoing Development - MSN
Is Artiva Biotherapeutics Inc. stock undervalued vs historical averagesJuly 2025 PreEarnings & Technical Pattern Based Signals - DonanımHaber
Artiva Biotherapeutics, Inc.(NasdaqGM: ARTV) dropped from NASDAQ Biotechnology Index - marketscreener.com
CEO Moves: Can Artiva Biotherapeutics Inc. stock rebound after recent weakness2025 Big Picture & High Accuracy Swing Entry Alerts - Улправда
Can Artiva Biotherapeutics Inc. stock rebound after recent weaknessJuly 2025 Drop Watch & High Accuracy Swing Entry Alerts - Улправда
Resistance Check: Can Artiva Biotherapeutics Inc. stock rebound after recent weaknessDividend Hike & Free Safe Entry Trade Signal Reports - Улправда
ARTV Stock Price and Chart — NASDAQ:ARTV - TradingView — Track All Markets
Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Artiva Biotherapeutics CEO sells $19,122 in stock By Investing.com - Investing.com Nigeria
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
Artiva Biotherapeutics (ARTV) Stock: Today’s News (Dec. 16, 2025), Why Shares Spiked, Analyst Forecasts, and What Investors Are Watching Next - ts2.tech
Insider Sell: Fred Aslan Sells Shares of Artiva Biotherapeutics Inc (ARTV) - GuruFocus
Insider Selling: Artiva Biotherapeutics (NASDAQ:ARTV) CEO Sells 3,187 Shares of Stock - MarketBeat
Artiva Biotherapeutics CEO sells $19,122 in stock - Investing.com
12 Health Care Stocks Moving In Monday's After-Market Session - Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session - Benzinga
US Stocks Mixed; NY Manufacturing Activity Dips In December - Benzinga
Wedbush Predicts Up to ~600% Jump for These 2 ‘Strong Buy’ Stocks - Yahoo Finance
Artiva Biotherapeutics Executes RSU Exchange for Employees - TipRanks
Artiva Biotherapeutics Advances with Promising NK Cell Therapy Study - MSN
Artiva Biotherapeutics executes RSU exchange for employees - MSN
Pre Market Movers: XCUR, VOR, MTVA Set The Path - RTTNews
Analysts Are Bullish on Top Healthcare Stocks: CG Oncology, Inc. (CGON), Nurix Therapeutics (NRIX) - The Globe and Mail
How Artiva Biotherapeutics Inc. stock trades before earningsPortfolio Growth Summary & Free Risk Controlled Daily Trade Plans - Newser
Will Artiva Biotherapeutics Inc. stock outperform tech sector in 2025Trade Exit Report & Consistent Profit Trading Strategies - Newser
Risk Hedge: Can Artiva Biotherapeutics Inc. stock rebound after recent weakness2025 Institutional Moves & Daily Growth Stock Tips - moha.gov.vn
A new trading data show Allarity Therapeutics Inc (ALLR) is showing positive returns. - Setenews
Analysts Set Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) Target Price at $19.00 - Defense World
Artiva Biotherapeutics (ARTV) Stock Analysis Report | Financials & Insights - Benzinga
LNP | LancasterOnline Events3rd Cell Therapy for Autoimmune Disease Summit - LancasterOnline
12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga
Why Artiva Biotherapeutics Inc. stock is seen as undervalued2025 Risk Factors & Reliable Momentum Entry Alerts - newser.com
Will Artiva Biotherapeutics Inc. stock beat EPS estimatesJuly 2025 Chart Watch & Fast Entry High Yield Stock Tips - newser.com
How resilient is Artiva Biotherapeutics Inc. stock in market downturnsWeekly Investment Report & Expert Curated Trade Ideas - newser.com
Is Artiva Biotherapeutics Inc. stock attractive for retirement portfoliosWeekly Market Report & Weekly Consistent Profit Watchlists - newser.com
Why Artiva Biotherapeutics Inc. stock could rally in 2025 - newser.com
Artiva Biotherapeutics Inc. stock daily chart insights2025 Historical Comparison & Expert Verified Stock Movement Alerts - newser.com
Is Artiva Biotherapeutics Inc. stock supported by strong cash flows2025 Investor Takeaways & Long-Term Growth Portfolio Plans - newser.com
ARTV: Off-the-shelf NK cell therapy for autoimmune disease advances toward pivotal RA trial with strong safety and funding - TradingView
Artiva Biotherapeutics (NASDAQ:ARTV) CEO Sells $21,547.50 in Stock - MarketBeat
Relative strength of Artiva Biotherapeutics Inc. in sector analysisSwing Trade & Free Weekly Watchlist of Top Performers - newser.com
Aslan Fred sells Artiva Biotherapeutics (ARTV) stock for $21,522 By Investing.com - Investing.com UK
Finanzdaten der Artiva Biotherapeutics Inc-Aktie (ARTV)
Es liegen keine Finanzdaten für Artiva Biotherapeutics Inc (ARTV) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):